Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries
Language English Country Great Britain, England Media print-electronic
Document type Comparative Study, Journal Article
PubMed
28181669
DOI
10.1111/ijd.13543
Knihovny.cz E-resources
- MeSH
- Acitretin therapeutic use MeSH
- Biological Products therapeutic use MeSH
- Cyclosporine therapeutic use MeSH
- Dermatologic Agents therapeutic use MeSH
- Diabetes Mellitus epidemiology MeSH
- Adult MeSH
- Phototherapy MeSH
- Hyperlipidemias epidemiology MeSH
- Hypertension epidemiology MeSH
- Body Mass Index MeSH
- Keratolytic Agents therapeutic use MeSH
- Comorbidity MeSH
- Coronary Disease epidemiology MeSH
- Quality of Life MeSH
- Middle Aged MeSH
- Humans MeSH
- Methotrexate therapeutic use MeSH
- Obesity epidemiology MeSH
- Retreatment MeSH
- Prevalence MeSH
- Psoriasis drug therapy epidemiology therapy MeSH
- Registries MeSH
- Retrospective Studies MeSH
- Risk Factors MeSH
- Severity of Illness Index MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Comparative Study MeSH
- Geographicals
- Czech Republic epidemiology MeSH
- Names of Substances
- Acitretin MeSH
- Biological Products MeSH
- Cyclosporine MeSH
- Dermatologic Agents MeSH
- Keratolytic Agents MeSH
- Methotrexate MeSH
BACKGROUND: BIOREP is a Czech registry of psoriatic patients on biological treatment in a clinical setting. We describe the characteristics of patients with psoriasis at the time of enrollment and present comparisons with published data from other national registries. METHODS: We analyzed the cohort of patients treated with biologics between May 2005 and May 2015. Demographic data, previous therapies, comorbidities, and severity of psoriasis were compared with data from other registries - DERMBIO, BIOBADADERM, BADBIR, and PSOBEST. RESULTS: A total of 1412 psoriatic patients initiating biological treatment were included with a predominance of males (63.4%). The mean patient age was 50.2 years, and approximately 70.5% of patients were either overweight or obese. The mean baseline Psoriasis Area and Severity Index was 19.8, and the Dermatology Life Quality Index was 16.6. More than one-third of patients (41.0%) reported a history of psoriatic arthritis, and a high proportion of patients (49.5%) with cardiovascular risk factors (hypertension [35.2%], hyperlipidemia [27.7%], diabetes mellitus [11.4%], coronary heart disease [4.9%], and obesity [15.2%]) were observed. Most of the patients had been previously treated with phototherapy (85.4%), acitretin (74.0%), methotrexate (65.7%), or cyclosporine (53.1%). CONCLUSION: BIOREP is one of the first registries of patients with psoriasis treated with biologics in Central and Eastern Europe. Our results found a similar or higher prevalence of comorbidities, long disease duration, and high impact on the quality of life among patients included in Western European registries.
References provided by Crossref.org
